Results 241 to 250 of about 564,426 (377)

NON HODGKINS LYMPHOMA: LARYNX [PDF]

, 2000
VK Shukul, LK KOCHHAR, Debaditya Roy
openalex   +1 more source

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial

Clinical Cancer Research, 2016
Chunmeng Wang, Zhi-qiang Wu, Yao Wang, Ye-lei Guo, Hanren Dai, Xiaohui Wang, Xiang Li, Yajing Zhang, Wen-ying Zhang, Meixia Chen, Yan Zhang, K. Feng, Yang Liu, Su-xia Li, Qing-ming Yang, W. Han   +15 more
semanticscholar   +1 more source

Late infections after high‐dose therapy and autologous stem cell transplantation for lymphoma: A Danish population‐based study

British Journal of Haematology, EarlyView.
Summary Infectious complications after high‐dose therapy and autologous stem cell transplantation (HDT‐ASCT) for lymphoma are the leading cause of late non‐relapse mortality. Characterizing the risk of infectious complications over time is important for rational follow‐up and because alternatives to HDT‐ASCT exist for some patients.
Freja Tang Severinsen, Mikkel Runason Simonsen, Eva Futtrup Maksten, Lasse Hjort Jakobsen, Rasmus Kuhr Jensen, Kirstine Kobberøe Søgaard, Paw Jensen, Peter de Nully Brown, Judit Mészáros Jørgensen, Thomas Stauffer Larsen, Christian Bjørn Poulsen, Tarec Christoffer El‐Galaly   +11 more
wiley   +1 more source

Coexistence of Tuberculous Lymphadenitis and Hodgkin Lymphoma: A Diagnostic Challenge. [PDF]

Cureus
Chandra M, Parmar M, Khilnani AK.
europepmc   +1 more source

A medical research council randomized trial in patients with primary cerebral non‐Hodgkin lymphoma [PDF]

, 2000
Graham M. Mead, Norman M. Bleehen, Anna Gregor, J. Bullimore, D. Shirley Murrell, R Rampling, J.T. Roberts, M.G. Glaser, P. L. Lantos, James W. Ironside, Timothy H. Moss, Michael Brada, Jill B. Whaley, Sally Stenning   +13 more
openalex   +1 more source

Classic Hodgkin Lymphoma [PDF]

Mayo Clinic Proceedings, 2018
Lori A. Erickson, Linda N. Dao
openaire   +2 more sources

Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post‐CAR‐T‐cell therapy

British Journal of Haematology, EarlyView.
Efficacy of chimeric antigen receptor (CAR) T‐cell therapy depends not only on tumour traits but also on the potency of CAR‐T cells. In clinical practice, the degrees of cell proliferation during CAR‐T‐cell manufacturing vary significantly among individual cases.
Tomoyasu Jo, Yasuyuki Arai, Tomoshige Shimizu, Toshio Kitawaki, Takashi Sakamoto, Chisaki Mizumoto, Junya Kanda, Momoko Nishikori, Kohei Yamashita, Miki Nagao, Akifumi Takaori‐Kondo   +10 more
wiley   +1 more source

Editorial: Health-related quality of life among Hodgkin lymphoma survivors. [PDF]

Front Oncol
Oliva EN, Fabbri A, Illès À.
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Trends of Non-Hodgkin Lymphoma Incidence Among Adults in the United States From 2000 to 2020. [PDF]

Cancer Rep (Hoboken)
Aslani A, Najafi M, Mousavi SE, Marandi H, Yekta Z, Nejadghaderi SA.   +5 more
europepmc   +1 more source